I. Introduction: A Trillion-Dollar Market in the Dark
According to the World Health Organization, approximately 338 million people worldwide live with visual impairment, of whom more than 43 million are blind. Since 2025, four converging technologies — artificial intelligence, neural electrodes, optoelectronic chips, and gene editing — have been advancing in parallel, ushering in the most intensive cycle of innovation the assistive vision field has ever seen.
This article maps three major technology tracks: wearable AI glasses, brain-computer interfaces (BCI), and retinal / cortical implants.
II. Wearable AI: From Hearing-Aid Logic to the "Second Pair of Eyes"
2.1 Market Landscape: Three-Way Competition
The specialist assistive track is led by Envision Glasses and OrCam MyEye, priced between $800 and $6,000. The consumer crossover track is anchored by Meta Ray-Ban, with the second-generation display version priced at around $299, integrating open-ear audio, AI visual Q&A, and real-time translation. Many low-vision users tend to own multiple device types to suit different contexts.
2.2 Technological Leap
Chinese research teams have developed wearable AI navigation systems that "analyse the environment in real time via camera and guide blind users around obstacles using voice commands and haptic feedback." Multimodal large models such as ChatGPT-4V and Gemini Ultra are upgrading glasses into context-aware, all-purpose assistants.
III. Brain-Computer Interfaces: Rewriting Neural Signals, Illuminating the Visual Cortex
3.1 Neuralink Blindsight
The Blindsight chip received FDA "Breakthrough Device" designation and plans to commence its first human trial in early 2026. It works by "implanting a microelectrode array directly into the brain's visual cortex, bypassing the damaged eye and optic nerve, and directly activating visual cortex neurons via images captured by an external camera."
Neuralink has completed 9 human implants of its N1 motor chip; the first recipient has achieved 10 hours per day of mind-controlled computer use.
3.2 A Multi-Track Race
The competitive landscape includes Cortigent's Orion system, Science Corporation's Gennaris bionic vision system, and Precision Neuroscience's Layer 7 cortical interface. The global BCI market in 2026 is projected to surpass $400 billion.
IV. Retinal Implants and Optogenetic Gene Therapy
4.1 The PRIMA Chip
Science Corporation's PRIMA photovoltaic subretinal implant achieved durable functional vision restoration in 38 patients with advanced geographic atrophy. The PRIMA microchip is implanted beneath the retina, where "each pixel generates a current proportional to the light it receives, directly stimulating the remaining retinal neurons." European regulatory approval is advancing, with a projected 2026 market launch.
4.2 Science Eye
Combining optogenetic gene therapy with an implantable flexible micro-LED display panel, Science Eye theoretically achieves resolution far exceeding PRIMA. It is currently in early development.
4.3 Gene Therapy
Three delivery routes — subretinal injection, suprachoroidal injection, and intravitreal injection — have produced differentiated approaches for different aetiologies. Multiple AAV gene therapy programmes for inherited retinal diseases have entered Phase II/III clinical trials.
V. A Macro View of Technology Trends
| Track | Target Population | Maturity | Timeline |
|---|---|---|---|
| Wearable AI Glasses | Full visual impairment spectrum | Commercially mature, rapidly iterating | Now |
| Retinal Implants (PRIMA etc.) | Mid–late-stage macular degeneration | Clinically validated, near market | 1–3 years |
| BCI (Blindsight etc.) | Total blindness | Early clinical trials | 5–10 years |
| Optogenetics + Gene Therapy | Inherited retinal disease | Phase II/III clinical | 3–7 years |
The fundamental difference among the three tracks lies in their level of intervention: wearable AI acts at the information layer, retinal implants at the photoreceptor layer, BCIs at the central processing layer, and gene therapy at the molecular layer.
VI. Three Barriers Beyond the Technology
First, affordability. Pricing remains in luxury territory. Meta Ray-Ban at $299 is an early signal of whether consumer-scale economics can drive costs down.
Second, rehabilitation. Post-implant patients require months of neural adaptation training, heavily dependent on specialist teams — a globally scarce resource.
Third, ethics and identity. Questions of bodily sovereignty, the boundaries of consciousness, and disability cultural identity are real. Some disability rights groups view the "correctivist" logic of these technologies with caution.
VII. Conclusion: Seeing as Reconstruction
Humanity is using silicon chips, photons, electrical current, and genes as its instruments — rewriting the connection between visually impaired people and the world. From $299 Ray-Bans to cortical electrodes, every track is advancing with determination in the spring of 2026.
China has the world's largest visually impaired population, formidable semiconductor manufacturing capacity, and growing neuroelectronics expertise. How to find the right position in the global landscape — bridging technological innovation with real-world deployment — is the defining challenge for medical technology companies of this era.